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AbstrACt
Introduction The prevalence of type 2 diabetes is 
rising steeply. National Health Service England (NHSE) 
is exploring the potential of a digital diabetes prevention 
programme (DDPP) and has commissioned a pilot with 
embedded evaluation.
Methods and analysis This study aims to determine 
whether, and if so, how, should NHSE implement a national 
DDPP, using a mixed-methods pretest and post-test design, 
underpinned by two theoretical frameworks: the Coventry, 
Aberdeen and London - Refined (CALO-RE) taxonomy of 
behavioural change techniques for the digital interventions 
and the Consolidated Framework for Implementation Research 
(CFIR) for implementation processes. In eight pilot areas 
across England, adults with non-diabetic hyperglycaemia 
(NDH) (glycated haemoglobin (HbA1c) 42–47 mmol/mol or 
fasting plasma glucose 5.5–6.9 mmol/L) and adults without 
NDH who are overweight (body mass index (BMI) >25 kg/
m2) or obese (BMI >30 kg/m2) will be referred to one of five 
digitally delivered diabetes prevention interventions. The 
primary outcomes are reduction in HbA1c and weight (for 
people with NDH) and reduction in weight (for people who 
are overweight or obese) at 12 months. Secondary outcomes 
include use of the intervention, satisfaction, physical activity, 
patient activation and resources needed for successful 
implementation. Quantitative data will be collected at baseline, 
6 months and 12 months by the digital intervention providers. 
Qualitative data will be collected through semistructured 
interviews with commissioners, providers, healthcare 
professionals and patients. Quantitative data will be analysed 
descriptively and using generalised linear models to 
determine whether changes in outcomes are associated with 
demographic and intervention factors. Qualitative data will be 
analysed using framework analysis, with data pertaining to 
implementation mapped onto the CFIR.
Ethics and dissemination The study has received 
ethical approval from the Public Health England Ethics 
and Research Governance Group (reference R&D 324). 
Dissemination will include a report to NHSE to inform 
future policy and publication in peer-reviewed journals.
IntroduCtIon
Diabetes is a national and international 
priority for health services, with a steeply 
rising prevalence. Globally, it affects over 
400 million people or around 9% of the adult 
population,1 and of these, over 90% have type 
2 diabetes mellitus (T2DM). There were an 
estimated 3.7 million people with diabetes in 
England in 2016–2017.2 People with diabetes 
are at risk of complications including cardio-
vascular disease, nephropathy, retinopathy 
and neuropathy. The costs of treating diabetes 
and its complications are estimated at 10% 
of the total National Health Service (NHS 
budget, or some £10 billion per annum.3 4 
Risk factors for developing T2DM include 
diet, lack of physical activity, obesity, genetic 
factors and deprivation. For many people, 
T2DM is a preventable illness, with preven-
tion focused on the modifiable factors of 
diet, physical activity and weight. There is 
high-quality international evidence that 
face-to-face programmes focusing on these 
three factors can reduce the rate of progres-
sion to T2DM in high-risk individuals.5–15 
To be successful, these programmes appear 
to require intensive sustained input over a 
prolonged period of time.7 In light of this 
strengths and limitations of this study
 ► This will be the first large-scale evaluation of digi-
tal diabetes prevention programmes internationally, 
and will provide data on effectiveness, uptake rates 
and on resources required for effective implemen-
tation, allowing a realistic determination of potential 
population impact.
 ► It benefits from real-world experience and data, pro-
viding strong external validity.
 ► The lack of a comparator or any randomisation 
means that any changes in outcomes observed 
during the study cannot be said to be due to the in-
terventions offered. Changes observed may be due 
to the impact of identification and measurement, 
the interventions offered, regression to the mean or 
some other unmeasured confounder.
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evidence NHS England (NHSE) launched Healthier 
You: The NHS Diabetes Prevention Programme (NHS 
DPP) in 2015, initially in seven demonstrator sites, and 
subsequently rolled out across England. All programmes 
within the NHS DPP must offer at least 16 hours of face-
to-face contact, spread over 13 sessions, with the total 
programme lasting at least 9 months.16
NHSE is also considering a national digital diabetes 
prevention programme (DDPP), and in order to 
generate the evidence to inform future policy in this area, 
launched a pilot DDPP in 2017, called ‘Healthier You: 
NHS DPP digital stream’.17 The reasons cited by NHSE 
for exploring the potential of a digital DPP are twofold: 
first, digital delivery may overcome some of the challenges 
affecting face-to-face programmes; and second, system-
atic review evidence that digital health interventions can 
be effective in increasing physical activity, changing diets 
and promoting weight loss,18–27 all behaviours which are 
effective in preventing T2DM. Challenges affecting the 
population impact of face-to-face programmes include 
problems of acceptability, as their intensive nature may 
make it difficult for people who work or have other 
commitments in their lives to attend; and there may be 
perceived stigma in attending a programme aimed at 
prevention of T2DM. Finally, the face-to-face programmes 
are costly, particularly when implemented at scale and a 
digital programme could potentially be easier to deliver 
at scale and more cost-effective.
However, there is little evidence to support these poten-
tial advantages,28 and there are some well-documented 
challenges in the delivery of digital health interventions. 
Three of the most important of these challenges are prob-
lems with engagement and adherence; concerns around 
the ‘digital divide’; and well-documented problems with 
implementation. Many digital health interventions show 
low rates of initial uptake as well as high rates of subse-
quent attrition from the intervention, which limits their 
potential for population impact.29 Moreover, there is 
uncertainty as to how best to improve engagement and 
adherence—although there are data which suggest that 
a certain amount of human input, for example, in the 
form of supportive or coaching telephone calls, can 
improve engagement, the requirement for human input 
can impact on the scaleability and costs of digital health 
interventions.30–32 There is real concern that the ‘digital 
divide’ (the divide between those who do and do not make 
regular use of digital technology) will exacerbate health 
inequalities, as many of those with greatest health needs 
(older people, people with long-term health problems 
and those with low incomes) are also people who make 
less use of digital technology.33–37 Third, the challenges 
of successful implementation of digital health interven-
tions are well known,38 39 with few examples of successful 
integration of digital health interventions into routine 
healthcare and considerable uncertainty as to how best to 
achieve such integration.
In the light of this potential, coupled with these 
major areas of uncertainty, NHSE commissioned a pilot 
DDPP with an associated evaluation to run alongside 
the national DPP. In the initial tender document, NHSE 
specified that the goal of the pilot and associated eval-
uation was to inform future policy in this area, and as 
such, the overarching aim of the evaluation was to deter-
mine: ‘Whether, and if so, how, should NHSE roll out a 
national DDPI at the end of the pilot?’ Specific areas of 
interest were around uptake, use and impact on weight 
and glycated haemoglobin (HbA1c); the likely impact of 
a digital programme on health inequalities; and how the 
interventions should be integrated into NHS workflows, 
including determining the resource requirements for 
successful implementation. Although a formal compar-
ison of the effectiveness of different interventions was 
out of scope, NHSE was interested in whether specific 
features of different interventions appeared to be asso-
ciated with variation in observed uptake, use or impact. 
The tender specified that a formal health economic anal-
ysis was out of scope. The evaluation is due to report in 
2020.
The specific objectives of the evaluation can be grouped 
into three areas: uptake, use and impact of the interven-
tions; the extent to which uptake, use and impact vary 
by socioeconomic status (SES) as an indicator of likely 
impact on health inequalities; and factors relating to 
implementation.
Objectives pertaining to uptake, use and impact:
1. Determine uptake and use of the digital diabetes pre-
vention interventions (DDPI) by people referred to 
them through the DDPP.
2. Determine the effects of DDPI on people referred to 
them through the DDPP.
3. Explore the extent to which these benefits vary accord-
ing to differences in key features of the selected DDPI.
4. Explore user views about the acceptability of DDPI, in-
cluding perceptions relating to use/non-use and im-
pact on relevant behaviours.
Objectives pertaining to health inequalities:
5. Explore the extent to which uptake, use and effects 
vary by SES.
Objectives pertaining to implementation:
6. Describe the various implementation strategies ap-
plied in the eight demonstrator sites.
7. Determine the costs associated with implementing and 
delivering a DDPP, from an NHS perspective.
8. Explore commissioner, healthcare professional and 
provider views about key factors influencing imple-
mentation, uptake and impact of the DDPI.
9. Summarise and synthesise these data in a report which 
can be used to inform the policy decisions about wheth-
er, and if so, how, to roll out a DDPP across England.
MEthods
design
Mixed-methods pretest and post-test design, under-
pinned by theory.
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theoretical frameworks
This evaluation will be underpinned by two theoret-
ical frameworks: one pertaining to the effectiveness of 
the DDPI and one pertaining to the implementation 
processes.
Understanding the likely and observed effectiveness 
of the selected DDPI will be promoted by applying the 
Coventry, Aberdeen and London - Refined (CALO-
RE) taxonomy of behaviour change techniques40 and 
describing interventions using the Template for Interven-
tion Description and Replication (TiDIER) framework41 
(online supplementary appendix 1).
To help with describing and understanding the imple-
mentation processes, we will use the Consolidated 
Framework for Implementation Research (CFIR).42 This 
specifies that the key constructs which determine whether 
an intervention is successfully implemented or not are: 
intervention characteristics; outer setting; inner setting; 
individual characteristics and the implementation process 
(for details see online supplementary appendix 2).
Patient and public involvement
The board overseeing the NSHE programme in diabetes 
and diabetes prevention is made up of a triumvirate of 
NHSE, Public Health England (PHE) and Diabetes UK 
(DUK). DUK is the largest charity representing the voice 
of people with diabetes in the UK. Patient and public 
involvement (PPI) in this study was, therefore, provided 
by DUK, through their membership of the board. This 
board determined how the DDPP should be piloted and 
evaluated, what the requirements for the evaluation were, 
including overall design (numbers of demonstrator sites, 
DDPI, pretest and post-test design, primary outcomes and 
duration of study). The board also provides oversight of 
the conduct and progress of the study and will receive 
the reports of the study. Hence, there was PPI input into 
determining the research questions, outcome measures, 
study design and dissemination.
setting
Eight demonstrator sites were selected by NHSE in 
parallel with the selection of the evaluator team, who had 
no input into site selection. Sites volunteered to partic-
ipate in the digital pilot, and were selected to achieve a 
range of geographies and demographies, including rural, 
semirural, urban and metropolitan areas, with widely 
varying proportions of people from black and minority 
ethnic backgrounds, SES and pre-existing levels of digital 
readiness and engagement with diabetes prevention.
Populations and participants
There were three populations specified by NHSE: (1) 
adults with non-diabetic hyperglycaemia (NDH) defined 
as having had an HbA1c measurement of 42–47 mmol/
mol, or a fasting glucose measurement of 5.5–6.9 mmol/L, 
in the 12 months prior to referral; (2) adults who are 
overweight (body mass index (BMI) of 25 to <30 kg/m2) 
without NDH and (3) adults who are obese (BMI of 30 
kg/m2 or over) without NDH. It is the responsibility of 
the eight demonstrator sites to determine how they will 
identify people who fell into these three populations, how 
general practitioner (GPs) and patients will be informed 
about the programme, and how patients will be referred 
to a DDPI. In most sites, patients will be referred to the 
interventions by their healthcare professionals, usually 
their GPs. In some areas, identification and referral may 
be undertaken by alternative providers contracted to 
undertake assessment of cardiovascular risk as part of 
the NHS Health Check Programme, which includes a 
two-stage assessment that aims to identify NDH and undi-
agnosed T2DM.43 Referring healthcare professionals are 
responsible for discussing the referral with patients, to 
ensure patients understand their diagnosis, the type of 
intervention they are being referred to and the expected 
benefits. Referring healthcare professionals are respon-
sible for sending the patient’s name and contact details to 
the relevant DDPI provider; that provider is then respon-
sible for contacting the patient and onboarding them to 
the intervention. These processes are identical to those 
used in the national face-to-face DPP,44 with the only 
difference being that the provider is offering a digital, 
rather than a face-to-face intervention.
Interventions
A total of five DDPI were selected following a multistage 
selection process undertaken by an independent assessor 
(Our Mobile Health) under contract to NHSE. Following 
widespread advertising of the opportunity, 84 companies 
registered an interest and underwent initial screening 
against six criteria. These were: (1) that the intervention 
supported behavioural change; (2) was available by June 
2017; (3) was localised for the English market; (4) was 
underpinned by an evidence-based approach; (5) did 
not require any further integration with existing health 
information technology (IT) systems before launching; 
(6) had a pricing system in place (although cost itself was 
not a criterion). Thirty providers met these criteria and 
progressed to a self-assessment exercise which explored 
eight criteria: safety; privacy and security; pricing; 
evidence based or indicators of effectiveness; usability 
and accessibility; technical stability; change management 
and interoperability. The self-assessment questionnaire 
can be found at https:// developer. nhs. uk/ daq.45 This 
led to a shortlist of 14 interventions, which were reviewed 
by subject matter experts including behaviour change 
theory experts, clinical safety officers, GPs, diabetologists, 
diabetes specialist nurses and dieticians. The final sample 
was selected to vary on factors known to be important in 
influencing uptake, use and effectiveness of digital health 
interventions, namely: the delivery platform (smartphone 
vs not); the amount of human interaction to promote 
uptake; and inclusion (or not) of wearables. Within this, 
interventions with better pre-existing evidence for uptake, 
use and effectiveness as well as capabilities and infrastruc-
ture to implement at scale, were prioritised.
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All five interventions focused on dietary intake, weight 
loss and physical activity, and all interventions set person-
alised goals and provided feedback on progress towards 
these goals.
Intervention A (Buddi Nujjer) is a smartphone app, 
which links to a wristband for monitoring physical activity. 
The participants log their eating habits and activities via 
the programme, receive three motivational messages 
from the app per day and complete a total of 22 learning 
modules over the course of the 12-month programme. 
Onboarding is done by an initial phone call and email 
for registration. A customer services team is available for 
those who have technical difficulties, but apart from that, 
the service is entirely digital.
Intervention B (Hitachi) is smartphone (Android and 
Apple), tablet and desktop compatible. The solution 
provides a hybrid of digital and non-digital interactions 
with a website and a series of phone calls with an expe-
rienced health advisor, whose advice follows NHS guide-
lines. Participants and health advisors set an action plan 
at the start of the programme. Participants then self-re-
port their outcomes and log their lifestyle on the website 
to understand their progress against key milestones and 
objectives. This information goes back to the health 
advisor team who prompt on guidance and can interact 
with participants. Health advisors contact participants 
monthly for the first 6 months and have one more step-
down call at the 8-month mark. Pedometers and scales 
can be provided on request. Onboarding is done through 
an initial brief phone call, at which point a longer, goal 
setting telephone call is arranged.
Intervention C (Liva) is smartphone (Android and 
Apple), tablet and desktop compatible. There is an 
initial face-to-face appointment with a health coach for 
onboarding and goal setting, followed by 26 coaching 
sessions with the same coach, delivered weekly for the 
first 12 weeks and then tapering off in frequency. There is 
an online peer support group.
Intervention D (Ourpath) is smartphone (Android and 
Apple), tablet and desktop compatible and includes wire-
less weighing scales and a wearable activity tracker. Partic-
ipants are entered into a peer group of up to 10 other 
people with similar goals who live locally. Groups interact 
by group messaging, and group targets are set as well as 
individual ones. The programme has three stages: the 
‘Core’ programme with daily education content received 
through the app for the first 6 weeks, the ‘Sustain’ 
programme with weekly education content until the 
6 month mark and the final 6 months where the user will 
have completed all the education modules but still have 
access to the dietician and group support. Onboarding is 
done through two phone calls —an initial introductory 
one, and a second one to set the participant up with the 
programme and group.
Intervention E (Oviva) is an app (Android and Apple 
compatible) with supporting material (learning materials, 
podcasts, recipes) delivered through an online portal. 
For patients without a smartphone, the content can be 
delivered via phone calls. The app allows users to track 
their activity, weight, and food and drink intake (using 
a photo food diary). The programme is a mix of digital 
and non-digital interactions with a series of phone calls 
accompanying the app. The programme is more intense 
at the start with a weekly phone call in the first 8 weeks 
to cover the 16-topic curriculum, tapering to a monthly 
phone call thereafter. The phone calls are all conducted 
by the same dietician who is a specialist diabetes dietician 
with at least 2 years experience. Onboarding is done by 
the dietician in the first phone call.
The interventions will be described according to the 
TiDIER Framework for describing complex interven-
tions41 and the CALO-RE Behaviour Change Technique 
taxonomy.40
outcomes
The primary outcomes were prespecified by NHS 
England, and were change between baseline and 12 
months in HbA1c for the population with NDH and 
weight for all three populations. Changes over 6 months 
are considered secondary outcomes.
Secondary and explanatory outcomes have been 
selected according to our pathway of action model, which 
posits that the DDPI achieves its goal of reducing a user’s 
risk of diabetes by promoting behavioural change, specif-
ically, promoting dietary change and an increase in phys-
ical activity. Taken together these behavioural changes 
result in reduced HbA1c and reduced weight. To achieve 
these changes requires the user to: register with the inter-
vention, use the intervention, initiate behaviour change 
and sustain behaviour change. Effects at each stage will be 
moderated by intervention factors and by patient factors 
(see figure 1). The context and implementation process 
will also affect the overall population uptake and impact.
Secondary outcomes are listed in table 1 and include 
intervention uptake, use and satisfaction; behavioural 
and clinical outcomes; and costs related to implemen-
tation, although it should be noted that a formal health 
economic analysis was excluded from the brief. Data will 
be collected at baseline, 6 months and 12 months.
Measures used are the Friends and Family Test (FFT)46 
to measure satisfaction with care, the International Phys-
ical Activity Questionnaire (IPAQ)47 to measure phys-
ical activity and the 13-item Patient Activation Measure 
(PAM-13).48
Demographic characteristics are collected at baseline 
only and will be used as explanatory factors. Demographic 
data to be collected includes age (date of birth), gender, 
ethnicity, postal code (to be used for determining SES 
by mapping against the Index of Multiple Deprivation 
(IMD)) and highest level of education attained.
Qualitative and explanatory outcomes
Reasons for observed differences in quantitative 
outcomes will be explored through qualitative interviews. 
These will be undertaken with a range of stakeholders, 
including commissioners/leads for the DDPP in selected 
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local health economies (LHE); healthcare professionals 
(GPs, practice nurses, diabetes nurses, healthcare assis-
tants, practice managers); digital diabetes intervention 
providers; the implementation teams charged with imple-
menting the DDPP in the selected LHE and patients.
Interviewees will be selected through purposive 
sampling, aiming for variation across geographical area, 
digital diabetes intervention provider, disciplinary back-
grounds and areas of high and low uptake. Recruitment 
of interviewees will continue until (1) all digital diabetes 
intervention providers and representatives from each 
demonstrator site have been interviewed and (2) data 
saturation is achieved.
Interviews will be conducted using semistructured topic 
guides, by trained interviewers, working for RSM. The 
topic guides will vary according to the background of the 
stakeholder, with the main areas covered summarised in 
table 2. Interviews will be undertaken in waves, with wave 
1 taking place during initial implementation and set-up, 
wave 2 once the programme is well established and wave 
3 towards the end of the pilot.
data collection
Referral forms will include basic demographic and clin-
ical data, including HbA1c and weight recorded in the 
previous 3 months to confirm eligibility.
Quantitative data
The DDPI providers are responsible for collecting all 
quantitative data. Baseline data will be obtained from 
referral forms and supplemented with data obtained 
during onboarding interviews with patients. Follow-up 
self-report data (FFT, IPAQ and PAM-13) will be collected 
online. HbA1c and weights will be measured by the DDPI 
providers or by patients’ general practices, with the 
method and site of measurement recorded.
HbA1c measurements may be done on either venous 
or capillary blood samples, using either registered 
NHS laboratories or validated point-of-care testing kits. 
Whichever measurement process is used at baseline 
should be used at follow-up. Weights will be recorded 
using calibrated scales, with patients wearing light 
indoor clothing.
data analysis
Quantitative data
The baseline characteristics of the three cohorts (NDH, 
overweight and obese) will be summarised with respect 
to sociodemographic characteristics, intervention 
uptake, behavioural and clinical outcomes and economic 
outcomes. Continuous data will be summarised in terms 
of the mean, SD and number of observations or, where 
skewed, median and IQR. Binary/categorical data will be 
summarised in terms of frequency counts and percent-
ages. Descriptive statistics will also be used to explore 
differences in baseline characteristics across the eight 
demonstrator sites and five DDPIs.
The primary analysis will be based on participants with 
complete data. For continuous outcomes, the overall 
effectiveness of the programme will be assessed in 
pre–post analyses by comparing the mean outcomes in 
each cohort from baseline to 6 months, and from base-
line to 12 months (presented with 95% CIs for the esti-
mated change in outcomes). The statistical significance 
of any changes will be assessed using a paired t-test. For 
Figure 1 Theory of change/pathway of action for effects of intervention. NB: all taking place within different contexts (local 
health economies) and with different implementation processes. HbA1c, glycated haemoglobin; SES, socioeconomic status.
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categorical outcomes, pre–post analyses will be conducted 
using McNemar’s test.
Multivariable generalised linear models will be used 
to determine whether changes in outcomes are associ-
ated with demographic factors, adjusting for baseline 
outcome scores. Where necessary, continuous outcomes 
will be transformed to ensure good regression model fit. 
Exploratory analysis of the influence of potential medi-
ators will be conducted by adding variables relating to 
usage and features of the DDPI to the regression models. 
The potential for clustering effects by demonstrator site 
will be considered by the inclusion of random effects for 
the demonstrator site in the generalised linear models. 
Three-level models accounting for clustering by GP prac-
tice within demonstrator sites will also be explored.
Reasons for missing data will be documented and 
the baseline characteristics of those with and without 
missing data compared. Although the primary analysis 
will be based on participants with complete data, we will 
undertake sensitivity analyses using various imputation 
models. The potential for bias due to non-random attri-
tion will be addressed by fitting a propensity score model 
to account for drop-out on the basis of baseline character-
istics and then using inverse probability weighting based 
on the propensity score to fit the treatment effectiveness 
model.49 No formal adjustment for multiple significance 
testing will be applied.
Sample size
Target referral and registration numbers were preset 
by NHSE as part of the tender at 3500 registrations for 
the NDH population and 1500 for the overweight/
obese population. We estimated minimum detectable 
effect sizes at 90% power and a 5% significance level 
for the key research questions, given these fixed sample 
sizes. Assuming a 25% completion rate (at 12 months), 
it will be possible to detect standardised effect sizes of 
d=0.11 and d=0.17 when assessing overall effectiveness 
Table 1 Quantitative outcomes
Population Time point for collection
NDH Overweight/obese Baseline 6 months 12 months
Primary Outcome HbA1c
Weight
Weight X X X
Secondary outcomes
Intervention factors
  Amount of human support 
planned and delivered (coaching, 
phone calls, emails).
X X X X
  Numbers referred X X X X X
  Numbers registered X X X X X
  Numbers who start to use the 
intervention
X X X X X
  Numbers who complete the 
intervention
X X X X X
  Usage data for each user X X X X X
  Friends and Families Test X X X X
Behavioural and clinical outcomes
  Height for calculation of BMI X X X
  Physical activity (IPAQ) X X X X X
  Patient activation (PAM-13). X X X X X
Economic outcomes
  Cost of the digital diabetes 
prevention intervention
X X X
  Types of staff involved in 
implementation in each LHE
X X X X X
  Time spent by each member of 
staff on implementation of the 
DDPP (estimated)
X X X X X
  Additional costs X X X X X
BMI, body mass index; DDPP, digital diabetes prevention programme; HbA1c, glycated haemoglobin; IPAQ, International Physical Activity 
Questionnaire; LHE, local health economies; NDH, non-diabetic hyperglycaemia; PAM-13, 13-tem Patient Activation Measure. 
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Table 2 Qualitative and explanatory outcomes
Stakeholder group Main areas of topic guide
Time point for collection
Wave 1 Wave 2 Wave 3
Local health 
economies  (LHE)
(commissioners, diabetes 
leads, health service 
managers) 
About the LHE: 
 ► Geography, demography and priorities 
 ► Culture and organisational style 
 ► Rationale for engaging with Digital Diabetes 
Prevention Programme (DDPP) (hopes, 
expectations, fears) 
X
About the digital diabetes prevention 
intervention (DDPI) selected 
 ► How and why this DDPI was selected 
 ► Views of the selected intervention 
X X X
About the implementation plan 
 ► Describe the implementation plan 
 ► Reflections on progress, strengths, 
weaknesses, amendments proposed or 
made 
X X X
Resources required 
 ► Types and numbers of staff involved 
 ► Time per staff member (estimated) 
 ► Other costs/resources 
X X X
Overall lessons learnt X
Healthcare professionals Local geography, demography and clinical 
priorities 
X
Understanding and prioritisation of DDPP X X X
Views about DDPI in use in local area X X X
Views about potential benefits / harms  of 
DDPP, including impact on health inequalities 
X X X
Views about implementation process locally X X X
Overall lessons for future national delivery X X
Digital Diabetes 
Programme Intervention 
Providers 
Describe the intervention X
Describe the evidence base for the intervention 
Onboarding process X
Views on how the implementation is going in 
participating LHE 
X X X
Explanations and reflections on reasons for 
successes/challenges in implementation 
X X X
Views on whether and how this programme 
could be scaled up nationally 
X X X
Observed usage and impact of intervention on 
patients and reasons for these
X X
Overall lessons learnt X X
Patients Knowledge about diabetes and its prevention X
Relative prioritisation of diabetes prevention X
Experience of DDPP including identification, 
referral, onboarding to DDPI, use of DDPI 
X
Reasons for use/non use of DDPI X
Impact of DDPI on lifestyle and health 
behaviours 
X
Preferences for digital versus face to face X
Suggestions for improvement X
Overall views about the programme X
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in the NDH and overweight/obese groups respectively, 
assuming clustering is ignorable. This compares favour-
ably with a weighted mean effect size of d=0.22 (95% CI 
0.20 to 0.23) estimated in a meta-analysis by Johnson et 
al50 for behaviour change interventions targeting eating 
and physical activity. Further power analysis allowing for 
clustering effects by demonstrator site (with an intra-
class correlation coefficient (ICC) of 0.02 based on a 
median estimate of 0.0185 in a study of ICCs in adults 
with diabetes in primary care practices51) gave minimum 
detectable effect sizes of d=0.18 and 0.22 in the NDH and 
overweight/obese groups, respectively, assuming a 25% 
completion rate at 12 months. For the purpose of anal-
ysis, completion is defined as obtaining data on weight 
and HbA1c at 12 months.
Qualitative data
Interviews will be recorded, transcribed verbatim and 
anonymised prior to analysis. Transcripts will be anal-
ysed using framework analysis52 which is well suited to 
policy-relevant research, with specific questions and a 
priori issues. The five steps of framework analysis are (1) 
familiarisation, (2) identifying a thematic framework; 
(3) indexing; (4) charting and (5) mapping and inter-
pretation. Familiarisation will be achieved by reading and 
rereading transcripts, with an a priori framework based 
on the CFIR used to index and chart the data. Data that 
cannot be coded using CFIR will be noted. Mapping and 
interpretation will take place in multidisciplinary data 
clinics where interpretations can be proposed, discussed 
and refined.
Ethics, research governance and data security
PHE is the sponsor for this research. 
Data security and information governance
Data will be handled according to the principles of the 
General Data Protection Regulation, the European Union 
framework for data protection which became law in the 
UK in May 2018.
Quantitative data
The DDPI providers will be responsible for obtaining 
and pseudonymising the quantitative data. No person-
ally identifiable data will be handled by RSM. Postal code 
mapping for IMD will be undertaken by the LHE (with 
support from RSM).
Qualitative data
1. Patients. Patients will be invited to participate in the 
interviews via the digital diabetes prevention providers 
and/or the LHE and will opt in to providing fully in-
formed consent for interviews.
2. Healthcare professionals, commissioners and provid-
ers. RSM has the contact details for these individuals as 
RSM is also responsible for the implementation of the 
DDPI. Written informed consent will be obtained prior 
to undertaking interviews.
Interview tapes will be stored securely on RSM servers. 
Only anonymised transcripts will be shared with the eval-
uation team outside RSM.
dissemination
Contracted outputs include a 12-month report to the 
funder, based on 6-month follow-up data, and a final 
report, based on 12-month follow-up data. The find-
ings will inform the scale of future provision of digital 
approaches within the NHS DPP.
Academic dissemination will also be undertaken in 
the form of conference presentations and publications 
in peer-reviewed journals. These presentations and 
publications will require advance approval from NHS 
England. Approval will not be unreasonably withheld, but 
academic dissemination may have to be delayed till after 
major policy decisions have been taken and made public.
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